The FDA has granted Breakthrough Therapy designation to idarucizumab (Boehringer Ingelheim), an investigational fully humanized antibody fragment (Fab), being evaluated as a specific antidote for Pradaxa (dabigatran etexilate mesylate).
Your search for dabigatran returned 105 results
No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants
Boehringer Ingelheim announced results from an interim analysis of the Phase 3 RE-VERSE AS patient study with idarucizumab for urgent reversal of the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate).
Resuming any anticoagulant found safer than stopping the drugs in these cases
Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a new study.
The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).
For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
Effective for dabigatran reversal among patients with uncontrolled bleeding, undergoing urgent surgery
Study of newer medications finds 16 percent receive too much or too little